Clinical-stage Biopharmaceutical Company Announces Negative Results From Clinical Study

On a day that saw its stock plummet by 84%, closing at $2.25, HilleVax, Inc. (Nasdaq: HLVX) announced the topline data results from its NEST-IN1 clinical study. This notable decline followed the announcement that the NEST-IN1 study did not meet its primary or secondary efficacy endpoints, leading the company to discontinue further development of its HIL-214 vaccine in infants. $HilleVax (HLVX.US)$